by Plus Therapeutics | Apr 15, 2024 | Uncategorized
#ICYMI: Plus Therapeutics added Dr. Andrew Brenner to our management team. Dr. Brenner will provide substantial input on the Company’s central nervous system cancer development programs while continuing to maintain his academic practice and laboratory. Full Press...
by Plus Therapeutics | Apr 11, 2024 | LM
📣 Mark Your Calendars! Plus Therapeutics will be exhibiting at the @livingbeyondbc Thriving Together Metastatic Breast Cancer Conference, April 19-21. Come learn about our ReSPECT-LM clinical trial for Leptomeningeal Metastases and meet some of our team. Event...
by Plus Therapeutics | Apr 10, 2024 | Uncategorized
#ICYMI : “Plus Therapeutics (PSTV), the Healthcare sector company, was revisited by a Wall Street analyst…Analyst Justin Walsh from JonesTrading maintained a Buy rating on the stock and has a $32.00 price target. Justin Walsh has given his Buy rating due...
by Plus Therapeutics | Apr 9, 2024 | Social
Tweets by plustxinc
by Plus Therapeutics | Apr 9, 2024 | Uncategorized
We would like to officially welcome Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. to the Plus Therapeutics Management Team! “As we prepare for the future, Plus is substantially strengthening its management in key areas such as cancer biology,...
Recent Comments